Revonto Injection, Powder, Lyophilized, For Solution
Product Images NDC 78670-003

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Revonto (NDC 78670-003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Uswm, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Revonto 01)

Chemical structure of dantrolene sodium, the active ingredient in Revonto injection. The diagram shows the molecular configuration including functional groups and sodium salt form.*

FDA Label Image

Principal Display Panel (20 mg Vial Carton)

Revonto 20 mg/vial lyophilized powder injection label for dantrolene sodium. The label indicates intravenous use and treatment for malignant hyperthermia. It shows six nonreturnable vials per package and the product is distributed by USWM, LLC, Louisville, KY. The label includes preparation instructions and storage conditions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.